LEKTI-CXCR4-ANP Composition for Broad-Spectrum Therapeutic Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack comprehensive solutions for a wide range of diseases including neurological disorders, cancers, dermatological conditions, viral infections, and inflammatory processes, with limited efficacy in managing conditions like stroke, Parkinson's disease, Alzheimer's, atopic dermatitis, and COVID-19.
Innovation Solution
A pharmaceutical composition comprising a serine proteinase inhibitor LEKTI, a peptide with antagonistic activity against natural CXCR4, and atrial natriuretic peptide (ANP), with specific amino acid sequence identities and modifications, is developed for broad-spectrum therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current treatments are used for neurological disorders, cancers, dermatological conditions, viral infections, and inflammatory processes, then specific diseases may be treated, but comprehensive efficacy across multiple disease types is limited
Solution Approach 1:
The pharmaceutical composition combines three distinct bioactive components (LEKTI, CXCR4 antagonist peptide, and ANP) into a single formulation that can treat multiple disease types including neurological disorders, cancers, dermatological conditions, viral infections, and inflammatory processes, achieving broad-spectrum therapeutic efficacy while maintaining reliability for each specific indication
Solution Approach 2:
The invention uses a composite pharmaceutical formulation containing multiple bioactive substances with different mechanisms of action. LEKTI provides serine proteinase inhibition, the CXCR4 antagonist peptide blocks chemokine signaling, and ANP offers natriuretic and vasodilating activities. This composite approach enables simultaneous treatment of diverse pathological conditions that respond to different mechanisms, resolving the contradiction between versatility and reliability
2Adaptability or versatility
If a pharmaceutical composition with multiple components is developed, then broad therapeutic coverage is achieved, but formulation complexity increases
Solution Approach 1:
The patent develops a universal pharmaceutical composition that addresses multiple disease mechanisms simultaneously. The formulation includes LEKTI for protease inhibition, CXCR4 antagonist for chemokine blockade, and ANP for natriuretic effects, creating a multi-functional treatment that covers neurological, oncological, dermatological, infectious, and inflammatory conditions in a single agent
Solution Approach 2:
The invention merges three separate therapeutic agents into one integrated pharmaceutical composition. By combining LEKTI, the CXCR4 antagonist peptide, and ANP in a single formulation, the patent simplifies administration while maintaining the complex therapeutic benefits of all three components, thereby managing formulation complexity while expanding disease coverage
Data Source
AI summary
Pharmaceutical composition comprising a) an amino acid sequence from at least 70% sequence identity to the amino acid sequence of a polypeptide selected from at least one of the 15 domains of the LEKTI polypeptide; and at least one selected from b) an amino acid sequence from at least 75% sequence identity to the amino acid sequence of a polypeptide with antagonistic activities against natural CXCR4; and c) an amino acid sequence from at least 70% sequence identity to the amino acid sequence of a natriuretic peptide (ANP).